Menu Search
Equities

United Therapeutics Corp

UTH:BRN

United Therapeutics Corp

Actions
  • Price (CHF)--
  • Today's Change--
  • Shares traded0.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year United Therapeutics Corp grew revenues 20.20% from 1.94bn to 2.33bn while net income improved 35.40% from 727.30m to 984.80m.
Gross margin88.94%
Net profit margin40.31%
Operating margin46.42%
Return on assets15.71%
Return on equity18.81%
Return on investment17.73%
More ▼

Cash flow in USDView more

In 2023, United Therapeutics Corp increased its cash reserves by 25.65%, or 246.50m. The company earned 978.00m from its operations for a Cash Flow Margin of 42.02%. In addition the company used 719.60m on investing activities and also paid 11.90m in financing cash flows.
Cash flow per share24.08
Price/Cash flow per share13.93
Book value per share136.74
Tangible book value per share134.23
More ▼

Balance sheet in USDView more

United Therapeutics Corp appears to have a strong balance sheet with enough cash in the capital structure to pay down 100% of the liabilities.
Current ratio4.58
Quick ratio4.41
Total debt/total equity0.0656
Total debt/total capital0.0615
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.